Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ebrotidine

S S Patel1, M I Wilde

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Ebrotidine, a novel H2 antagonist, offers gastroprotection by enhancing cell proliferation and mucus properties. It effectively treats ulcers and erosive reflux esophagitis, showing superior healing in smokers compared to ranitidine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole genome sequencing and characteristics of extended-spectrum beta-lactamase producing <i>Escherichia coli</i> isolated from poultry farms in Banaskantha, India.

Frontiers in microbiology·2022
Same author

Visuomotor control in mice and primates.

Neuroscience and biobehavioral reviews·2021
Same author

Technique to manage intraoperative cuff leak from damaged endotracheal tube pilot balloon.

International journal of oral and maxillofacial surgery·2021
Same author

Metagenomic of clinically diseased and healthy broiler affected with respiratory disease complex.

Data in brief·2018
Same author

Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience.

International journal of laboratory hematology·2018
Same author

Complete Genome Sequence of Brucella abortus SKN 13 Isolated from Placenta of Aborted Cattle in Gujarat, India.

Genome announcements·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Ebrotidine represents a new class of H2 receptor antagonists.
  • It possesses significant gastroprotective properties beyond simple acid suppression.

Purpose of the Study:

  • To evaluate the gastroprotective mechanisms and clinical efficacy of Ebrotidine.
  • To compare Ebrotidine's efficacy against H2 receptor antagonists like ranitidine and cimetidine.

Main Methods:

  • Assessed Ebrotidine's effects on gastric mucosal damage induced by ethanol, aspirin, and stress.
  • Compared antisecretory and anti-Helicobacter pylori activities with ranitidine and cimetidine.
  • Conducted clinical trials for gastric/duodenal ulcers and erosive reflux esophagitis, including a subgroup of smokers.

Main Results:

Related Experiment Videos

  • Ebrotidine stimulates epithelial cell proliferation and improves gastric mucus physicochemical properties.
  • It exhibits potent antisecretory activity, exceeding cimetidine and comparable to ranitidine.
  • Demonstrated synergistic anti-H. pylori activity, inhibiting urease and proteolytic enzymes.
  • Achieved comparable efficacy to ranitidine in treating ulcers and esophagitis, with superior healing rates in smokers.

Conclusions:

  • Ebrotidine offers multifaceted gastroprotection through enhanced mucus properties and antisecretory action.
  • Its anti-H. pylori activity and synergistic potential make it a valuable therapeutic agent.
  • Ebrotidine is clinically effective for acid-related disorders and shows promise for smokers.